|Table of Contents|

Efficacy comparison of TACE,immunotherapy combined with lenvatinib and bevacizumab in the treatment of advanced liver cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 17
Page:
3264-3269
Research Field:
Publishing date:

Info

Title:
Efficacy comparison of TACE,immunotherapy combined with lenvatinib and bevacizumab in the treatment of advanced liver cancer
Author(s):
WU Lin; LIU Xiaochen; DUAN Jianfeng; DUAN Changhu; YANG Fan
Department of Hepatobiliary Sugery,Xi'an Jiaotong University School of Medicine Affiliated Hanzhong 3201 Hospital,Shaanxi Hanzhong 723000，China.
Keywords:
advanced liver cancer; sintilimab; bevacizumab; lenvatinib; AFP
PACS:
R735.7
DOI:
10.3969/j.issn.1672-4992.2024.17.016
Abstract:
Objective:To investigate the difference in efficacy of TACE,sintilimab combined with bevacizumab and TACE,sintilimab combined with lenvatinib in the treatment of advanced liver cancer and the successfulconversion surgery.Methods:Fifty-two patients with advanced liver cancer who could not be resected by primary surgery were randomly divided into control group(n=27) and observation group(n=25).The control group received TACE,sintilimab combined with lenvatinib,while the observation group received TACE,sintilimab combined with bevacizumab.The treatment effect,tumor marker changes,adverse reactions and surgical transformation were compared between the two groups.Results:After 3 cycles of treatment,there was no significant difference in the indexes between the two groups(P＞0.05).After 6 cycles of treatment,the decreased level of AFP,objective response rate(ORR) and disease control rate(DCR) of the observation group were better than those of the control group(P＜0.05).And 4 patients who were operable after transformation were in the observation group.However,due to the small number of adverse reactions between the two groups,the difference is not significant.Conclusion:After 6 cycles of treatment,the decreased levels of AFP,ORR and DCR of the observation group are better than that of the control group.With the increase of the sample size,it may be confirmed that the success rate of surgical transformation in the observation group is higher,and the effect of the observation group is faster than that of the control group.

References:

[1]SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2021,71(3):209-249.
[2]LLOVET JM,KELLEY RK,KELLEYRK,et al.Hepatocellular carcinoma［J］.Nat Rev Dis Primers,2021,7(1):6.
[3]CHEN W,ZHENG R,BAADE PD,et al.Cancer statistics in China,2015［J］.CA Cancer J Clin,2016,66(2):115-132.
[4] TORRE LA,BRAY F,SIEGEL RL,et al.Global cancer statistics,2012［J］.CA Cancer J Clin,2015,65(2):87-108.
[5] LIU J,XIE S,DUAN X,et al.Assessment of efficacy and safety of the transcatheter arterial chemoembolization with or without apatinib in the treatment of large hepatocellular carcinoma［J］.Cancer Chemother Pharmacol,2020,85(1):69-76.
[6]BROWN ZJ,TSILIMIGRAS DI,RUFF SM,et al.Management of hepatocellular carcinoma：a review［J］.JAMA Surg,2023,158(4):410-420.
[7]CAPPELLE M,AGHAYAN DL,VAN DER POELMJ,et al.A multicenter cohort analysis of laparoscopic hepatic caudate lobe resection［J］.Langenbecks Arch Surg,2020,405(2):181-189.
[8]HELLMANN MD,PAZ-ARES L,BERNABE CR,et al.Nivolumab plus ipilimumab in advanced non-small-cell lung cancer［J］.N Engl J Med,2019,381(21):2020-2031.
[9]LIAO YY,BAI YX.The mechanism and research progress of PD-1/PD-L1 inhibitor in the treatment of advanced hepatocellular carcinoma［J］.Modern Oncology,2021,29(11):1989-1993.
[10] EL-KHOUEIRY AB,SANGRO B,YAU T,et al.Nivolumab in patients with advance-ed hepat-ocellular carcinoma(checkmate 040)：an open-label,non-comparative,phase 1/2 dose escalation and expansion trial［J］.Lancet,2017,389(10088):2492-2502.
[11] YAU T,PARK JW,FINN RS,et al.Nivolumabversus sorafenib in advanced hepatocellular carcinoma(checkmate 459)：a randomised,multicentre,open-label,phase 3 trial［J］.Lancet Oncol,2022,23(1):77-90.
[12]IYER RV,MAGUIRE O,KIM M,et al.Dose-dependent sorafenib-induced immunesuppression is associated with aberrant nfat activation and expression of PD-1 in T cells［J］.Cancers(Basel),2019,11(5):681.
[13] SEMAAN A,DIETRICH D,BERGHEIM D,et al.CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia［J］.Virchows Arch,2017,470(2):185-196.
[14] LIU J,PARK K,SHEN Z,et al.Immunotherapy,targeted therapy,and their cross talks in hepatocellular carcinoma［J］.Front Immunol,2023:14:1285370.
[15]DENG QJ,XIE LQ,LI H,et al.Overexpressed MALAT1 promotes invasion and metastasis of gastric cancer cells via increasing EGFL7 expression［J］.Life Sci,2016,157:38-44.
[16] LEE MS,RYOO BY,HSU CH,et al.Atezolizumab with or without bevaci-zumab in unresectable hepatocellular carcinoma(GO30140)：an open-label,multicentre,phase 1b study［J］.Lancet Oncol,2020,21(6):808-820.
[17] FINN RS,IKEDA M,ZHU AX,et al.Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma［J］.Clinical Trial,2020,38(26):2960-2970.
[18] KUDO M,FINN RS,QIN S,et al.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma：a randomised phase 3 noninferi-ority trial［J］.Clinical Trial,2018,391(10126):1163-1173.
[19] BRUIX J,QIN S,MERLE P,et al.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment(RESORCE)：a randomised,double-blind,placebo-controlled,phase 3 trial［J］.Clinical Trial,2017,389(10064):56-66.
[20] ABOU-ALFA GK,MEYER T,CHENG AL,et al.Cabozantinib in patients with advanced and progressing hepatocellular carcinoma［J］.N Engl J Med,2018,379(1):54-63.
[21] ZHU AX,KANG YK,YEN CJ,et al.Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations(REACH-2)：a randomised,double-blind,placebo-controlled,phase 3 trial［J］.Clinical Trial,2019,20(2):282-296.

Memo

Memo:
-
Last Update: 2024-07-31